CSIMarket
 
Praxis Precision Medicines Inc   (PRAX)
Other Ticker:  
 
 
Price: $55.1400 $2.14 4.038%
Day's High: $57.1629 Week Perf: 3.88 %
Day's Low: $ 52.55 30 Day Perf: 30.39 %
Volume (M): 450 52 Wk High: $ 59.98
Volume (M$): $ 24,824 52 Wk Avg: $22.57
Open: $53.28 52 Wk Low: $11.85



 Market Capitalization (Millions $) 364
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -123
 Cash Flow (TTM) (Millions $) 20
 Capital Exp. (TTM) (Millions $) 0

Praxis Precision Medicines Inc
Praxis Precision Medicines Inc is a biopharmaceutical company focused on discovering and developing targeted therapies for patients suffering from central nervous system disorders. The company leverages its expertise in neuroscience and genetic research to identify novel drug targets and develop precision medicines that address the underlying causes of these disorders. Praxis aims to provide patients with personalized treatments that can improve their quality of life.


   Company Address: 99 High Street Boston 2110 MA
   Company Phone Number: 300-8460   Stock Exchange / Ticker: NASDAQ PRAX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Praxis Precision Medicines Inc

Praxis Precision Medicines Inc Reports $2.45 Million in Revenue for Q4 2023, Despite Net Deficit

Praxis Precision Medicines Inc Sees Positive Revenue Growth Despite Net Deficit in Q4 2023
Praxis Precision Medicines Inc, a major player in the field of precision medicine, recently announced its financial results for the October to December 2023 period. Despite reporting a net deficit of $-26.878 million, the company saw a significant improvement compared to the deficit of $-41.173 million in the same reporting season a year ago. Additionally, Praxis Precision Medicines Inc claimed a net loss of $-123.28 million and revenue of $2.45 million for the financial year 2023.
The company's performance is a clear indication of its progress and potential in the precision medicine market. Praxis Precision Medicines Inc is actively working towards its goal of developing innovative treatments and breakthroughs in precision medicine. The company's dedication to this field is evident in its recent announcement regarding inducement grants under Nasdaq Listing Rule 5635(c)(4).

Shares

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): A Promising Future for Precision Medicine

Published Fri, Feb 2 2024 9:00 PM UTC



Praxis Precision Medicines, Inc. made an exciting announcement regarding inducement grants under Nasdaq Listing Rule 5635(c)(4). This move comes at a time when the company's share price is soaring, indicating its positive market performance. As of the writing of this article, Praxis Precision Medicines Inc's share price stands at $43.73, reflecting a remarkable inc...

Shares

Praxis Precision Medicines Announces Successful Pricing of $150 Million Public Offering

Published Thu, Jan 11 2024 12:30 PM UTC



Leading biopharmaceutical company, Praxis Precision Medicines, Inc. (NASDAQ: PRAX), has recently made a significant breakthrough by successfully pricing its underwritten public offering at $150.0 million. The offering, which consists of shares of common stock and pre-funded warrants, highlights Praxis' commitment to translating genetic insights into developing ther...

Shares

Praxis Precision Medicines Proposes Public Offering, Aiming to Expand Therapeutic Development for CNS Disorders

Published Wed, Jan 10 2024 9:19 PM UTC


BOSTON, Jan. 10, 2024 - Praxis Precision Medicines, a leading clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, has recently announced its plans for a proposed public offering of its common stock. The company aims to utilize the proceeds from the offering to further advance their innovative genetic-based...

Clinical Study

Praxis Precision Medicines Surpasses Expectations in Promising Study for Precision Epilepsy Treatment

Published Mon, Jan 8 2024 1:01 PM UTC

Praxis Precision Medicines, a leading biopharmaceutical company focused on developing precision therapies for central nervous system disorders, recently released an update on the progress of its clinical stage portfolio. In particular, the company reported positive preliminary analysis from the 15 mg cohort in the PRAX-628 study involving epilepsy patients with Photo-Paroxys...






 

Praxis Precision Medicines Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Praxis Precision Medicines Inc does not provide revenue guidance.

Earnings Outlook
Praxis Precision Medicines Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com